Teenager who received Elevidys, Sarepta’s Duchenne gene therapy, dies
Elevidys was approved after intense debate at the FDA, as officials and reviewers disagreed over how strong the evidence was ...
Zacks Investment Research on MSN3d
SRPT Nosedives 27% on Patient Death Following DMD Therapy Infusion
Shares of Sarepta Therapeutics SRPT plunged more than 20% yesterday after the company reported the death of a patient after ...
BioSpace2d
In Wake of Elevidys Death, Duchenne Patient Community Vows to Push On
After Sarepta reported the death of a patient who had recently taken the gene therapy Elevidys, patient advocacy group Parent ...
pharmaphorum3d
Sarepta slumps on Elevidys patient death
The tragic death of the 16-year-old boy came as a result of acute liver failure, which is a known side effect of Elevidys and ...
BioPharma Dive4d
Duchenne patient dies after receiving Sarepta gene therapy
A young man treated with Elevidys died of acute liver failure. The case may give doctors pause before prescribing the ...
MPR1d
Patient Dies Following Treatment With DMD Gene Therapy Elevidys
The Company is currently analyzing the case and will update the prescribing information for Elevidys to note this development.
Sarepta: Should Investors Run For The Exit?
Sarepta stock may recover sharply as additional information and data reveal that the adverse event reported by the company is ...
Why Sarepta Therapeutics Inc. (SRPT) Went Up On Wednesday?
Wednesday’s 10 Top Performers. In this article, we are going to take a look at where Sarepta Therapeutics Inc. (NASDAQ:SRPT) ...